<DOC>
	<DOCNO>NCT01907529</DOCNO>
	<brief_summary>The trial design study efficacy safety neoadjuvant docetaxel , epirubicin combination cyclophosphamide ( DEC ) plus human recombinant endostatin ( endostar ) breast cancer patient . The hypothesis protocol combine active angiogenesis agent chemotherapy could enhance pathological responce rate benefit breast cancer patient .</brief_summary>
	<brief_title>A Trail Neoadjuvant Endostar Combination With Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm invasive breast cancer ( core needle biopsy breast cancer diagnosis fine needle aspiration lymph node metastasis diagnosis ) Age 1870 No evidence distant metastasis No previous therapy Normal hematologic function No abnormality renal liver function Written inform consent With allergic constitution possible allergic reflection drug use study Any concurrent uncontrolled medical psychiatric disorder History severe heart disease , include congestive heart failure , unstable angina , uncontrolled arrhythmia , myocardial infarction , uncontrolled high blood pressure , heart valve disease Being pregnant nursing</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>